Peptides for Weight Loss: Which Options Have Evidence?

Some peptide medicines have strong evidence and FDA-approved uses for weight management. Examples include semaglutide, tirzepatide and liraglutide in specific prescription products. A website calling something a “weight-loss peptide” does not tell you whether that product has the same evidence, approval or expected benefit.

Start with the exact medicine, the reason it is being offered and the care that comes with it. This guide focuses on adult weight management in the United States; status was checked on October 8, 2026.

A practical comparison

These are selected options, not every obesity treatment. “Eligible adults” below means adults with obesity, or overweight plus at least one weight-related condition; individual suitability still needs assessment.

Molecule or offer	Product and route	What the evidence and status mean
Semaglutide	Wegovy: weekly injection or daily tablet	Approved for weight management in eligible adults. The formulation matters. Current label
Tirzepatide	Zepbound: weekly injection	Approved for weight management in eligible adults. Current label
Liraglutide	Saxenda: daily injection	Approved for weight management; its own trial results and label apply. Current label
Retatrutide	Investigational compound	Not a component of an FDA-approved drug. FDA says it cannot be used in compounding under federal law. FDA
Compounded GLP-1 product	Pharmacy-specific preparation	Compounded drugs are not FDA-approved. A medical need for compounding is a separate question from whether an approved medicine works. FDA

For adult medication discussions, NIDDK describes common eligibility thresholds as a BMI of at least 30, or at least 27 with a weight-related health problem. BMI is one part of the assessment. Your history, other medicines, possible adverse effects and preferences also matter. NIDDK guidance

“Peptide” and “GLP-1” are different labels

Peptide describes molecular structure. GLP-1 describes a hormone pathway that certain medicines act on. They overlap, but they are not interchangeable categories.

For example, orforglipron is a nonpeptide GLP-1 receptor agonist studied in the ATTAIN-1 trial. FDA approved it as the oral medicine Foundayo for weight management in eligible adults in April 2026. That makes it relevant to a treatment conversation even though it does not belong in a list of peptide molecules. FDA approval announcement

Likewise, a “GLP-1 support” supplement or patch should not inherit the evidence for a prescription drug. Read our GLP-1 patch claim check before treating those descriptions as equivalent.

How to read a weight-loss claim

If an advertisement gives a percentage, ask for enough context to understand it:

1. Which product and formulation were studied? The molecule’s name alone is incomplete.
2. Who participated? Adults with diabetes, adults without diabetes and adolescents are different study populations.
3. How long was treatment? A year-long result is not a first-month expectation.
4. What was the comparison? A placebo-controlled trial and a direct comparison between medicines answer different questions.
5. Which participants were included in the estimate? Ask how stopping treatment and missing results were handled.

Our semaglutide versus tirzepatide comparison applies this approach to a direct randomized trial. Avoid making a league table by lifting the largest number from unrelated studies. A population average cannot promise your outcome.

What a useful care plan includes

Think beyond obtaining a prescription. Before starting, ask who will explain the medicine, respond when something feels wrong and review whether treatment is helping.

The named products above are used alongside nutrition and activity measures. Long-term treatment may be appropriate when it remains effective and tolerable; stopping can be followed by weight regain. Discuss maintenance at the beginning, including what happens if cost or side effects interrupt your plan. NIDDK treatment guidance

Ask your team to review medical and family history, pregnancy plans, current medicines and supplements. The product’s full safety information matters more than an online “best peptide” ranking. For everyday preparation, use our food and routines guide.

Bring these questions to your appointment

• What health goal are we treating, and how will we measure progress?
• Which exact product are you considering, and why does its evidence fit me?
• Is this use covered by its FDA labeling? If not, what supports it?
• What symptoms should prompt a message, a same-day call or urgent care?
• What support is available between appointments?
• What is the complete ongoing cost, including visits, medication and any necessary tests?
• When will we reassess, and what is the maintenance plan?

Save the clinician-question checklist and compare the full bill using our GLP-1 cost guide. You do not need to arrive knowing which drug to request. Arriving with clear goals and good questions is a useful start.

Sources and further reading

1. Wegovy prescribing information, revised June 2026 (opens in a new tab)
2. Zepbound prescribing information, revised August 2026 (opens in a new tab)
3. Saxenda prescribing information, revised February 2026 (opens in a new tab)
4. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (opens in a new tab)
5. FDA: Foundayo approval, April 1, 2026 (opens in a new tab)
6. Wharton et al.: Oral nonpeptide orforglipron, ATTAIN-1 trial (opens in a new tab)
7. NIDDK: Prescription medications to treat overweight and obesity (opens in a new tab)

Sources checked October 8, 2026. Prices, labels and policies can change. Linked studies being peer reviewed does not mean this article has been clinically reviewed.